GOSS

0.84

0.11% -0.0009

Handel nachbörslich: .81 -0.03 -3.57%

Gossamer Bio Inc (GOSS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$0.8409

Offen:

$0.83

24-Stunden-Volumen:

846.49K

Relative Volume:

0.65

Marktkapitalisierung:

$190.35M

Einnahmen:

Nettoeinkommen (Verlust:

$-179.82M

KGV:

-0.3801

EPS:

-2.21

Netto-Cashflow:

$-159.16M

1W Leistung:

-9.68%

1M Leistung:

+20.60%

6M Leistung:

+47.76%

1J Leistung:

-1.44%

1-Tages-Spanne:

$0.7902

$0.8499

1-Wochen-Bereich:

$0.76

$0.93

52-Wochen-Spanne:

$0.4993

$1.60

Gossamer Bio Inc Stock (GOSS) Company Profile

Firmenname

Gossamer Bio Inc

Sektor

Healthcare (1176)

Branche

Biotechnology (673)

Telefon

(858) 922-0718

Adresse

3013 SCIENCE PARK, SAN DIEGO, CA

Mitarbeiter

135

Twitter

@GossamerBio

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

GOSS's Discussions on Twitter

Vergleichen Sie GOSS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
GOSS Gossamer Bio Inc	0.84	190.35M	0	-179.82M	-159.16M	-1.33
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-06-25	Eingeleitet	Oppenheimer	Outperform
2024-04-05	Fortgesetzt	Wedbush	Outperform
2023-07-27	Herabstufung	UBS	Buy → Neutral
2023-03-07	Herabstufung	Raymond James	Outperform → Mkt Perform
2023-03-01	Eingeleitet	Guggenheim	Neutral
2022-12-07	Herabstufung	Barclays	Overweight → Equal Weight
2022-12-07	Herabstufung	JP Morgan	Neutral → Underweight
2022-12-07	Herabstufung	SMBC Nikko	Outperform → Neutral
2022-10-20	Eingeleitet	Goldman	Buy
2022-09-21	Eingeleitet	JP Morgan	Neutral
2022-09-19	Eingeleitet	Wedbush	Outperform
2022-04-18	Eingeleitet	Raymond James	Outperform
2022-04-06	Eingeleitet	UBS	Buy
2022-01-10	Hochstufung	SMBC Nikko	Neutral → Outperform
2021-11-09	Fortgesetzt	Cantor Fitzgerald	Overweight
2021-09-21	Fortgesetzt	Piper Sandler	Overweight
2020-06-29	Eingeleitet	H.C. Wainwright	Buy
2020-04-22	Eingeleitet	Piper Sandler	Overweight
2020-02-27	Eingeleitet	Barclays	Overweight
2019-12-03	Fortgesetzt	BofA/Merrill	Buy
2019-10-30	Eingeleitet	Berenberg	Buy
2019-03-05	Eingeleitet	Barclays	Overweight
2019-03-05	Eingeleitet	BofA/Merrill	Buy
2019-03-05	Eingeleitet	Evercore ISI	Outperform
2019-03-05	Eingeleitet	SVB Leerink	Outperform

Alle ansehen

Gossamer Bio Inc Aktie (GOSS) Neueste Nachrichten

Dec 16, 2024

The Manufacturers Life Insurance Company Boosts Stock Position in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World

Dec 16, 2024

Dec 03, 2024

US Penny Stocks: 3 Picks With Market Caps Under $200M - Simply Wall St

Dec 03, 2024

Dec 02, 2024

XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio - The Manila Times

Dec 02, 2024

XOMA Royalty Acquires Pulmokine for $20 Million Adding the - GlobeNewswire

Dec 02, 2024

XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio - Benzinga

Dec 02, 2024

Nov 29, 2024

Gossamer Bio: Q3 Earnings Snapshot - Marketscreener.com

Nov 29, 2024

Nov 26, 2024

Adicet Bio Inc (NASDAQ: ACET) – Analysts’ Revisions Point To Positive Sentiment - Stocks Register

Nov 26, 2024

GSA Capital Partners LLP Invests $67,000 in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World

Nov 26, 2024

Nov 25, 2024